As a cholinesterase inhibitor, cabalatine bitartrate can improve the effect of succinylcholine-type muscle relaxant. Therefore, before anesthesia, there should be a suitable interval to stop taking this product. This product should not be used with other cholinergic drugs, and it may interfere with its action when used with anticholinergic drugs (see drug interaction). Because of its pharmacological effects, cholinesterase inhibitors may have vagal tone on heart rate. Therefore, like other cholinergic drugs, patients with sick sinus syndrome (SSS) or other heart block must be extra cautious when taking this product (see adverse reactions). Cholinergic nerve excitation can cause an increase in gastric acid secretion. Although there is no evidence of obvious deterioration of the corresponding symptoms during the clinical trial, patients with high risk of gastric ulcer, such as patients with a history of ulcer or patients receiving concomitant treatment with non-steroidal anti-inflammatory drugs, should be used with caution. Like other cholinergic drugs, patients with a history of asthma or other obstructive pulmonary diseases should be cautious in using carbazate bitartrate. Cholinergic drugs can aggravate urinary tract obstruction and seizures. Caution is advised when treating patients with this condition. At the initial stage of treatment, 1.5mg, twice a day, gradually increased to the patient's maintenance dose. If the treatment is interrupted for more than a few days, it should be restarted with the lowest daily dose to reduce the possibility of adverse reactions (such as severe vomiting) (see usage and dosage). One case reported that after 8 weeks of drug withdrawal, the treatment was resumed at an inappropriate dose (4.5mg), and severe vomiting and esophageal laceration occurred. Carbalatine bitartrate can cause dizziness and fatigue, especially at the beginning of treatment or when the dose is increased. No motor function damage was found in patients treated with this product. However, the attending physician should regularly evaluate the ability of patients with Alzheimer's disease to continue driving or operating machines. Incremental dose: As with other cholinergic drugs, adverse reactions were observed in a short time after increasing the drug dose. It can be improved by reducing the dose. In some cases, you need to stop using this product. Like other cholinergic drugs, carbamazepine may aggravate the symptoms of extravertebral body. It has been found that the symptoms of Parkinson's disease, especially tremor, will be aggravated in dementia patients with Parkinson's disease treated with this product. No motor function damage was found in patients treated with this product. However, the attending physician should regularly evaluate the ability of patients with Alzheimer's disease to continue driving or operating machines.